Wide Ranks

INDP

Indaptus Therapeutics, Inc.

1.03

Top Statistics
Market Cap 10 M Forward PE -0.7464 Revenue Growth 0.00 %
Current Ratio 3.88 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.2920 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 7 M Total Cash Per Share 0.7160 Total Debt 130802
Total Debt To Equity 2.12 Current Ratio 3.88 Book Value Per Share 1.44
All Measures
Short Ratio 54.00 % Message Board Id finmb_278220029 Shares Short Prior Month 34151
Return On Equity -1.27 City New York Uuid a1d498dc-072a-31b7-a80f-484137d2b2e5
Previous Close 1.04 First Trade Date Epoch Utc 1 B Book Value 1.44
Beta 1.13 Total Debt 130802 Volume 45748
Price To Book 0.7168 Last Split Date 1 B Fifty Two Week Low 0.8400
Total Cash Per Share 0.7160 Shares Short Previous Month Date 1 B Target Median Price 8.50
Max Age 86400 Sand P52 Week Change 0.3133 Target Mean Price 8.50
Net Income To Common -15747112 Short Percent Of Float 0.0183 Implied Shares Outstanding 10 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 31260
Average Volume10days 31260 Total Cash 7 M Next Fiscal Year End 1 B
Held Percent Insiders 0.2667 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.04 Target Low Price 5.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.24 Open 1.02
Free Cashflow -7414601 State NY Dividend Yield 0.00 %
Return On Assets -0.7112 Time Zone Short Name EST Trailing Eps -1.70
Day Low 1.01 Address1 Three Columbus Circle Shares Outstanding 10 M
Price Hint 4 Target High Price 12.00 Website https://indaptusrx.com
52 Week Change -0.5442 Average Volume 112317 Forward Eps -1.39
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 378.70 %
Last Split Factor 1:4 Regular Market Day High 1.06 Is_sp_500 False
Profit Margins 0.00 % Debt To Equity 2.12 Fifty Two Week High 3.10
Day High 1.06 Shares Short 138698 Regular Market Open 1.02
Industry Key biotechnology Earnings Growth 0.00 % Revenue Growth 0.00 %
Shares Percent Shares Out 0.0136 Operating Cashflow -12750747 Currency USD
Time Zone Full Name America/New_York Market Cap 10 M Is_nasdaq_100 False
Zip 10019 Quote Type EQUITY Industry Biotechnology
Long Name Indaptus Therapeutics, Inc. Regular Market Day Low 1.01 Held Percent Institutions 0.0599
Current Price 1.03 Address2 15th Floor Enterprise To Ebitda -0.2920
Financial Currency USD Current Ratio 3.88 Industry Disp Biotechnology
Number Of Analyst Opinions 2 Country United States Float Shares 7 M
Two Hundred Day Average 1.88 Enterprise Value 4 M Forward PE -0.7464
Regular Market Volume 45748 Ebitda -16478794 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products.

Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.

The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021.

Indaptus Therapeutics, Inc. is headquartered in New York, New York.